Skip to Content
Merck
CN
All Photos(1)

Documents

AB733

Sigma-Aldrich

Anti-Tamm-Horsfall Glycoprotein Antibody

serum, Chemicon®

Sign Into View Organizational & Contract Pricing

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

sheep

antibody form

serum

antibody product type

primary antibodies

clone

polyclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

immunodiffusion: suitable
immunohistochemistry: suitable
western blot: suitable

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... UMOD(7369)

Specificity

One arc by 2D-IEP against Tamm-Horsfall glycoprotein (1 mg/mL). No precipitin line by IEP against normal human plasma. Identity verified by double immunodiffusion.

Immunogen

Highly purified human Tamm-Horsfall glycoprotein (uromucoid) from urine; >95% pure by SDS-PAGE.

Application

IEP: 100 μL antiserum vs. 5 μL uromucoid (50 mg/L)

RID and Rocket RID: 10 μL antiserum/cm2 in gel vs. 5 μL uromucoid (50 mg/L), NT - 1/5

Double diffusion: 10 μL antiserum vs. 3 μL uromucoid (50 mg/L)

*Note: The use of 3% PEG 6000 with 1.2% agarose in a suitable buffer (such as TBE or Tris-barbital pH >8.2) is recommended for the above applications.

Immunohistochemistry

Optimal working dilution must be determined by the end user.
Research Category
Inflammation & Immunology
Research Sub Category
Immunoglobulins & Immunology
This Anti-Tamm-Horsfall Glycoprotein Antibody is validated for use in ID, WB, IH for the detection of Tamm-Horsfall Glycoprotein.

Physical form

In glycine buffered saline, pH 7.4 containing 0.1% sodium azide, 0.1% E-Amino-n-Caproic Acid, 0.01% Benzamidine and 1 mM Ethylenediaminetetraacetic acid as preservatives.

Storage and Stability

Maintain at 2-8°C in undiluted aliquots for up to 12 months.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Somchai Chutipongtanate et al.
The Journal of clinical investigation, 115(12), 3613-3622 (2005-11-26)
Previous research on proteins that inhibit kidney stone formation has identified a relatively small number of well-characterized inhibitors. Identification of additional stone inhibitors would increase understanding of the pathogenesis and pathophysiology of nephrolithiasis. We have combined conventional biochemical methods with
Fernanda Chacar et al.
Physiological reports, 5(11) (2017-06-04)
Proteinuria is a marker and mediator of chronic kidney disease (CKD). In clinical practice, the urinary protein-to-creatinine ratio (UP/C) is of limited usefulness, because it indicates only the magnitude of proteinuria and not the origin of the loss (glomerular or
Shinji Sasaki et al.
BMC genomics, 17(1), 724-724 (2016-09-11)
Hydrallantois is the excessive accumulation of fluid within the allantoic cavity in pregnant animals and is associated with fetal mortality. Although the incidence of hydrallantois is very low in artificial insemination breeding programs in cattle, recently 38 cows with the
Jenni Karttunen et al.
International journal of molecular sciences, 22(9) (2021-06-03)
Urinary extracellular vesicles (EVs) and their RNA cargo are a novel source of biomarkers for various diseases. We aimed to identify the optimal method for isolating small (<200 nm) EVs from human urine prior to small RNA analysis. EVs from
Brian M Nolen et al.
PloS one, 8(5), e63368-e63368 (2013-06-01)
The analysis of protein biomarkers in urine is expected to lead to advances in a variety of clinical settings. Several characteristics of urine including a low-protein matrix, ease of testing and a demonstrated proteomic stability offer distinct advantages over current

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service